TRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies.

  • Post author:
  • Post category:

Therapeutic Candidate or Device An allogenic, off the shelf, engineered regulatory T cell product that mimics the function of T regulatory Type 1 (Tr1) cells. Indication Prevention of acute and…

Continue ReadingTRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies.

IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration

  • Post author:
  • Post category:

Therapeutic Candidate or Device Polarized Retinal Pigment Epithelium-Secreted Factors (PRPE-SF) Indication Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy) Therapeutic Mechanism PRPE-SF is comprised of multiple secreted factors produced from stem…

Continue ReadingIND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration

Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia

  • Post author:
  • Post category:

Therapeutic Candidate or Device Hematopoietic stem/progenitor cells collected from patients with hypophosphatasia and genetically modified with a lentiviral vector to release TNALP Indication Hypophosphatasia (HPP) Therapeutic Mechanism We are proposing…

Continue ReadingEx vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia